生華生物科技股份有限公司 SENHWA BIOSCIENCES INC.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma 2021-08-19 10:57
Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19 2021-08-16 15:29
Senhwa Signs Agreement with Taiwan's CDE for COVID-19 Program Guiding Development of Silmitasertib 2021-08-14 10:48
Senhwa Announces IND Submission to India's CDSCO of a Phase II Clinical Study for Silmitasertib as a Potential COVID-19 Treatment 2021-06-23 19:00
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19 2021-01-22 12:00
Senhwa Biosciences Presents Positive Cholangiocarcinoma Data 2021-01-15 22:00
Senhwa Biosciences Receives US FDA 'Study May Proceed' Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461 2020-12-24 10:40
Senhwa Biosciences's Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium 2020-12-14 10:09
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19 2020-12-03 22:17
Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations 2020-11-26 10:34
CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients 2020-11-06 22:00
Senhwa Announces Multiple IND application submissions to U.S. FDA for Silmitasertib as a Potential Treatment for COVID-19 2020-11-02 22:00
Coronavirus Breakthrough: Senhwa Reports First eIND Silmitasertib Treated Severe COVID-19 Patient - Discharged Following Five Days of Treatment 2020-09-12 08:34
Senhwa Biosciences's Silmitasertib Receives Rare Pediatric Disease Designation from U.S. FDA for Treatment of Recurrent Sonic Hedgehog Medulloblastoma 2020-07-07 21:00
Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19 2020-07-01 21:00
Senhwa Biosciences Silmitasertib Named as Potential COVID-19 Therapy 2020-03-31 19:00
Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS 2019-12-13 04:00
Senhwa Biosciences Silmitasertib / Basal Cell Carcinoma Trial Completed 1st Patient Enrollment 2019-04-17 19:00
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA 2018-11-01 13:30
PBTC and Senhwa sign cooperation agreement to develop CX-4945 for pediatric brain tumor treatment 2018-06-12 21:00
1 2 3